Mature a2-plasmin inhibitor in human plasma has 12 more Nterminal residues than hitherto anticipated. The first residue is the methionine at position 28, downstream from the N-terminus of the pre-protein. The cDNA sequence predicts that the site cleaved upon formation of the mature inhibitor is a typical signal-peptidase recognition site. The mature inhibitor (464 residues) and the previously reported, and presumably degraded,
INTRODUCTION
a2-Plasmin inhibitor (a2-PI) belongs to the a.-proteinase-inhibitor class of the serine-proteinase-inhibitor superfamily (serpins) [1] . It is synthesized by the liver [2] . Its target proteinase is plasmin, which is the key enzyme in fibrinolysis. a2-PI contains three regions of importance for efficient inhibition ofplasmin-catalysed fibrin degradation. From the N-terminus they are as follows: (1) the region containing the Gln residue which is cross-linked to fibrin in an activated coagulation factor XIII-catalysed reaction; (2) the region with the reactive-centre loop; and (3) the region with the secondary binding site for the plasmin(ogen) kringle structures 1-3 (Kl + 2 + 3). The last-mentioned region is located in a C-terminal extension, which among serpins is unique for a2-PI.
The complete primary structure of human a2-PI has been deduced from the cDNA sequence [3, 4] and from amino-acidsequence analysis ofa2-PI purified from plasma [5] . The combined sequencing data suggested that the pre-form of a2-PI is composed of 491 amino-acid residues, where the first 39 N-terminal residues constitute the signal peptide and the rest the mature protein with an N-terminal asparagine residue (452 residues). Recently, human a2-PI was expressed in a baby-hamster-kidney (BHK) cell line [6] . Amino-acid-sequence analysis of the N-terminus of the recombinant protein revealed that it contained an additional 12 residues, starting with the methionine at position 28 downstream from the N-terminus of pre-a2-PI. Evidence was provided that these additional residues had to be cleaved off in order to achieve optimal cross-linking of a2-PI to fibrin, and thereby efficient inhibition of plasmin generated on the fibrin surface [6] .
The above-mentioned difference in the N-terminus of plasma and recombinant a2-PI led us to re-investigate the structure of the inhibitor in human plasma. It is demonstrated that a2-PI with each of the N-termini is indeed present in human plasma. cyclohexane-l-carboxylic acid (tranexamic acid) and D-ValLeu-Lys-4-nitroanilide (S-2251) were from Chromogenix, M6lndal, Sweden. Plasminogens with N-terminal glutamic acid (Glul-plasminogen, i.e. residues 1-791) and N-terminal lysine (Lys78-plasminogen, i.e. residues 78-791) and plasmin were those used previously [7] . The Kl + 2 + 3 fragment of plasminogen was prepared from Glul-plasminogen as described by SottrupJensen et al. [8] . Kl + 2 + 3-Sepharose (3.5 mg of Kl + 2 + 3/ml of packed gel) was prepared by coupling KI + 2 + 3 to CNBractivated Sepharose 4B (Pharmacia LKB, Uppsala, Sweden) as described by the manufacturer. Rabbit immunoglobulin raised against human a2-PI (anti-a2-PI) was from DAKO, Glostrup, Denmark.
MATERIALS

Purfication of human Y-PI
The source of a2-PI was plasma obtained from blood stabilized by 0.123 vol. of 24.7 mM citric acid/141.9 mM trisodium citrate/25.5 mM NaH2PO4/204.4 mM glucose (CPD-solution). Plasma was frozen within 4 h of blood collection, stored at -40°C and used within 6 months. a2-PI was purified at 4°C from four portions of plasma. Each portion (500-1000 ml) originated from three to five donors. The purification procedure involved three steps: first removal of plasminogen by adsorption to lysine-Sepharose 4B, and then fractional (NH4)2SO4 precipitation of the plasminogen-depleted plasma as described previously [9] ; finally affinity chromatography on KI + 2 + 3-Sepharose [10] . The precipitate obtained between 0.8 M and 2.7 M (NH4)2SO4 in step 2 was dissolved in 250 ml of 0.04 M sodium phosphate, pH 7.4, and dialysed against the same buffer. Then the dialysate was incubated for 60 min with 80 ml of Kl + 2 + 3-Sepharose. The gel was filtered and washed on a Buchner funnel with 0.04 M sodium phosphate, pH 7.4, until Al% 280 of the effluent was less than 0.05. The washed gel was poured into a XK 16/40 column (Pharmacia LKB, Uppsala, Sweden) and a2-PI was eluted at a flow rate of 50 ml/h with the same buffer containing 1 mM tranexamic acid. Fractions containing a2-PI were pooled and dialysed against Tris/HCl buffer. The purified inhibitor was analysed by modified crossed immunoelectrophoresis with Lys78-plasminogen in the first-dimension Abbreviations used: Glu1-plasminogen, plasminogen with N-terminal glutamic acid (residues 1-791); Lys78-plasminogen, plasminogen with mainly N-terminal lysine (residues 78-791); Kl +2+3, kringle structures 1-3 (residues 73/79-354) prepared by elastase cleavage of plasminogen; a2-PI, a2-plasmin inhibitor; Met'-a2-PI, a2-PI with N-terminal methionine (residues 1-464); Asn13-ca2-PI, a2-Pl with N-terminal asparagine (residues ; tranexamic acid, trans-4-(aminomethyl)cycl.ohexane-1-carboxylic acid; BHK, baby-hamster kidney.
TT whprm correspondence.should.be addressed. 623 gel (retards migration of a2-PI with an intact C-terminus) and anti-a2-PI in the second-dimension gel as described by Kluft and Los [11] . It showed that the C-terminal extension containing the secondary binding site for the plasmin(ogen) KI + 2 + 3 structures was intact in the purified a2-PI preparations.
Analysis of protein concentration
The concentration of plasmin was determined by measuring the initial rate of hydrolysis of D-Val-Leu-Lys-4-nitroanilide (390 mM) in Tris/HCl buffer at 25°C [12] , using values for Km of 150 mM and kcat of 15.2 s-'. The concentration of a2-PI was determined by active-site titration of a known amount of plasmin with the inhibitor as described [9, 13] .
N-terminal-sequence analysis
The purified a2-PI was contaminated with Glu'-plasminogen and other minor impurities. amino acids (residues Met-27-Pro'2) as previously suggested [3, 4] . This is compatible with the fact that the scissile Ala-'-Met' peptide bond is a much more likely signal-peptidase cleavage site than the scissile Pro12-Asn'3 peptide bond [6, 14] . The most Table 2) . Two parallel sequences were obtained one (sequence A) was identical with the earlier reported sequence of cz2-PI [5] . By subtraction a second sequence could be identified, which is shown as sequence B. Values given are the yields obtained in the individual cycle corrected for background levels in the previous cycle(s) and lag in the following cycle. SDS/PAGE analysis SDS/PAGE in a 6% (w/v) acrylamide gel without urea was performed as described previously [9] .
Sequence
RESULTS AND DISCUSSION
Reduced SDS/PAGE of preparations of purified plasma a2-PI showed an homogeneous band with an Mr of approx. 67000 (results not shown). N-terminal-sequence analysis of the purified inhibitor revealed two parallel sequences (Table 1) . One (sequence A) was identical with that reported earlier for plasma ax2-PI [5] , starting with the asparagine residue at position 40 downstream from the N-terminus of pre-a2-PI [3, 4] (Figure 1 ). The other (sequence B) started with the methionine residue at position 28 downstream from the N-terminus of pre-a2-PI. From these results it is concluded that the liver secretes mature a2-PI with 12 more N-terminal residues than hitherto anticipated [3] [4] [5] , and that the previously reported inhibitor with N-terminal asparagine (Asn3-_a2-PI) is a proteolytically modified form. For this reason the N-terminal methionine is assigned as residue number 1, and not number -12 [3, 4] , throughout the paper. About equal amounts of Met'-a2-PI (residues 1-464) and Asn13-cX2-PI (residues 13-464) were found in each of four different inhibitor preparations (Table 2) . Our results agree with the finding that Met'-a2-PI is expressed by BHK cell line transfected with genomic material coding for the entire inhibitor [6] . Furthermore, they strongly support the proposal that the signal peptide is composed of 27 amino acids (residues Met-27-Ala-1) [6] , and not of 39 [4] ). (b and c) These sequences were found by N-terminal sequence analysis of purified human a2-PI. The sequence in (b) is identical with the N-terminal sequence of recombinant Met-ca2-PI [6] . The sequence in (b) is identical with the N-terminal sequence originally found in a2-PI [5] . (1 ) indicates the signal-peptidase-cleavage site deduced from the data in this paper and from the results of Sumi et al. [6] : (t) indicates the signal-peptidase-cleavage site originally proposed [3, 4] . The protein numbering is based on the a2-PI form with an N-terminal methionine residue. Table 2 Relative amounts of the os2-PI forms in four preparations The total amounts of Met1-aC2-PI and Asn13-a2-Pl were calculated as the mean of the yields of the five first amino-acid residues of each sequence. The yields were calculated as described for preparation no. 1 in Table 1 residues flanking the scissile peptide bond [14] . The preferred P3 residue mentioned in the order of decreasing frequency is Ala, Gly, Ser, Cys or Thr; the P3 residue cannot be aromatic, charged or large and polar. Furthermore, the P3 to P' residues cannot be proline. In the case of the scissile Ala-'-Met' peptide bond all these criteria are fulfilled (P3= Val; P, = Ala). This is not the case with the scissile Pro12-Asn13 peptide bond (P3 = Ser; P3= Pro), since P3 is not allowed to be Pro. It remains to be determined whether the Pro12-Asn13 peptide bond is cleaved in vivo or in vitro after blood collection. An intracellular prolyl endopeptidase with high specificity towards Pro-Xaa peptide bonds is present in various tissues [15] . It is unlikely that this enzyme cleaves the Pro12-Asn13 peptide bond in a2-PI, since its function appears to be limited to proteolytic modification of oligopeptides (hormones and neuropeptides). The extracellular metalloproteinases stromelysin (MMP-3) and human polymorphonuclear leucocyte collagenase cleave a Pro357-Met358 peptide bond in the reactive-centre loop of acproteinase inhibitor, leading to inactivation of the inhibitor [16] [17] [18] . These proteinases may be candidates for the cleavage of the Pro'3-Asn13 peptide bond in a2-PI.
In order to investigate if plasma Met'-ac2-PI reacted with its target enzyme, purified ox2-PI (containing both N-terminal forms) and plasmin (each at a concentration of 2 ,M) in Tris/HCl buffer were incubated for 15 min at room temperature. Then a non-reduced sample of the reaction mixture was subjected to SDS/PAGE. Inspection of the gel showed that all a2-PI and plasmin were converted into enzyme-inhibitor complex (results not shown), thus demonstrating that both N-terminal forms of the inhibitor form stable complexes with plasmin. This agrees with the observation that the rates of inhibition of plasmin by recombinant Metl-a2-PI and plasma Asn13-c02-PI were very similar [6] .
It has been reported that recombinant Met1-ax2-PI, as well as a recombinant inhibitor form with a tripeptide extension on the Nterminal side of Asn 3, is significantly less cross-linked to fibrin than is plasma Asn'-cc2-PI by activated coagulation factor XIII [6, 19] . This suggests that N-terminal modification of Met'-ox2-PI, forming Asn13-cL2-PI, is a physiological regulatory mechanism of importance in fibrinolysis, since cross-linking of the inhibitor to fibrin markedly reduces plasmin-catalysed fibrin resolution [20] . Proteolytic cleavage of the reactive-centre loop of a2-PI leading to inactivation of the inhibitor may be another physiological regulatory mechanism [9, 21, 22] . This also applies to the proteolytic release of the C-terminal secondary plasmin(ogen) binding site of a2-PI, the loss of which markedly decreases the rate of inhibition ofplasmin [9] . Significant amounts of a2-PI lacking this binding site are present in plasma [9, 11] . C-terminal proteolytic modification changing inhibitor function has also been reported for a1-anti-chymotrypsin, a,-proteinase inhibitor and antithrombin III [16] [17] [18] . ax-Anti-chymotrypsin, a,-proteinase inhibitor and plasminogen activator inhibitor 1 exhibit heterogeneity of the N-terminus (for references see Lindmark et al. [23] ). The functional implication of this heterogeneity is unknown.
In conclusion, Met'-a2-PI is the mature inhibitor of plasmincatalysed fibrinolysis in the blood, the reactivity of which may be both positively and negatively regulated by N-and C-terminal proteolytic modification respectively.
